EYLEA 2 mg is indicated for adults for the treatment of visual impairment due to diabetic macular oedema (DMO).

In response to the challenge of treatment burden in clinics, EYLEA 2 mg's posology in DMO has been updated to reflect current clinical practice.

INDIVIDUALISE TREATMENT FOR YOUR DMO PATIENTS

After five initial monthly doses, the EYLEA 2 mg treatment interval is extended to 2 months. Based on the physician’s judgement of visual and/or anatomic outcomes, treatment interval can then be maintained at bimonthly dosing for the first year followed by T&E, or further extended up to 16 weeks using proactive T&E dosing.*

Adapted from EYLEA 2 mg Summary of Product Characteristics.

EYLEA 2 mg posology in DMO

*The recommended dose for EYLEA is 2 mg aflibercept equivalent to 0.05 mL. EYLEA treatment is initiated with one injection per month for five consecutive doses, followed by one injection every 2 months. Based on the physician’s judgement of visual and/or anatomic outcomes, the treatment interval may be maintained at 2 months or individualised, such as with a T&E dosing regimen, where the treatment intervals are usually increased by 2-week increments to maintain stable visual and/or anatomic outcomes. There are limited data for treatment intervals longer than 4 months. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly. Treatment intervals shorter than 4 weeks have not been studied. The schedule for monitoring should be determined by the treating physician. If visual and anatomic outcomes indicate that the patient is not benefiting from continued treatment, EYLEA should be discontinued.

Abbreviations

DMO, diabetic macular oedema. mCNV, myopic choroidal neovascularisation. nAMD, neovascular age-related macular degeneration. Q8, every 8 weeks. RVO, retinal vein occlusion. T&E, treat and extend.